Comparison of the biochemical responses to human parathyroid hormone-(1-31)NH2 and hPTH-(1-34) in healthy humans

被引:36
作者
Fraher, LJ
Avram, R
Watson, PH
Hendy, GN
Henderson, JE
Chong, KL
Goltzman, D
Morley, P
Willick, GE
Whitfield, JF
Hodsman, AB
机构
[1] Univ Western Ontario, St Josephs Hlth Ctr, Dept Med, London, ON N6A 4V2, Canada
[2] Univ Western Ontario, St Josephs Hlth Ctr, Dept Biochem, Lawson Res Inst, London, ON N6A 4V2, Canada
[3] McGill Univ, Dept Med, Montreal, PQ H3A 2T5, Canada
[4] McGill Univ, Dept Physiol, Montreal, PQ H3A 2T5, Canada
[5] CNR, Inst Biol Sci, Ottawa, ON, Canada
关键词
D O I
10.1210/jc.84.8.2739
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The 1-31 fragment of human PTH [hPTH-(1-31)NH2] has been shown, like hPTH-(1-34), to have anabolic effects on the skeletons of ovariectomized rats when given intermittently, but, unlike hPTH-(1-34), it does so without affecting serum calcium concentrations and does not activate the protein kinase C second messenger pathway in some target cells. To investigate the biochemical responses to hPTH(1-31) in humans, we have directly compared it to hPTH-(1-34) during the course of slow infusions of each. Ten healthy adults, five men and five women, aged 26 +/- 5 yr (range, 22-37), each received 8-h continuous infusions of 8 pmol/kg.h hPTH-(1-34) and hPTH-(1-31) given in random order at least 2 weeks apart. During the infusions there were significant increases in both plasma and urinary cAMP (P < 0.05), but there were no differences in the responses between the two peptides (P = 0.362 for plasma; P = 0.987 for urine). There were also significant phosphaturic and natriuretic responses to the two peptides, which again were not different between peptides. During the infusion of hPTH-(1-34) serum ionized calcium (Ca2+) increased from 1.21 +/- 0.033 to 1.29 +/- 0.046 mmol/L (P < 0.01), and endogenous hPTH-(1-84) decreased from 29.6 +/- 9 to 15.0 +/- 5.7 pg/mL (P < 0.01) such that there was a negative correlation between them (r(2) = 0.45). However, when hPTH-(1-31) was infused, neither serum Ca2+ (1.24 +/- 0.03 us. 1.25 +/- 0.03) nor hPTH-(1-84) (26.8 +/- 5 vs. 30.7 +/- 12 pg/mL) was affected. Circulating concentrations of 1,25-dihydroxyvitamin D-3 increased from 92 +/- 42 to 131 +/- 63 pmol/L (P < 0.05) during infusion of hPTH-(1-34) and from 92 +/- 27 to 110 +/- 42 pmol/L (P = NS) during hPTH-(1-31) infusion. There was also a significant increase in the urinary measure of type I collagen degradation of aminoterminal telopeptides from 78 +/- 45 to 101 +/- 51nmol/mmol creatinine (P < 0.05) when hPTH-(1-34) was infused, but it was not affected (68 +/- 30 us. 66 +/- 24 nmol/mmol creatinine) by hPTH-(1-31). Therefore, hPTH-(1-3) appears to be equivalent and equipotent to hPTH(1-34) in the release of cAMP from target tissues and the renal handling of phosphate and sodium. However, at the doses employed, it does not increase serum calcium, is a weaker stimulator of the 25-hydroxyvitamin D-1 alpha-hydroxylase, and does not induce rapid bone resorption.
引用
收藏
页码:2739 / 2743
页数:5
相关论文
共 33 条
[1]   PARATHYROID-HORMONE FOR THE PREVENTION OF BONE LOSS INDUCED BY ESTROGEN DEFICIENCY [J].
FINKELSTEIN, JS ;
KLIBANSKI, A ;
SCHAEFER, EH ;
HORNSTEIN, MD ;
SCHIFF, I ;
NEER, RM .
NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (24) :1618-1623
[2]   Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34) - A randomized controlled trial [J].
Finkelstein, JS ;
Klibanski, A ;
Arnold, AL ;
Toth, TL ;
Hornstein, MD ;
Neer, RM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (12) :1067-1073
[3]   RADIOIMMUNOASSAY OF 1,25-DIHYDROXY VITAMIN-D2 - STUDIES ON THE METABOLISM OF VITAMIN-D2 IN MAN [J].
FRAHER, LJ ;
ADAMI, S ;
CLEMENS, TL ;
JONES, G ;
ORIORDAN, JLH .
CLINICAL ENDOCRINOLOGY, 1983, 19 (02) :151-165
[4]   A COMPARISON OF THE INVIVO BIOCHEMICAL RESPONSES TO EXOGENOUS PARATHYROID HORMONE-(1-34) [PTH-(1-34)] AND PTH-RELATED PEPTIDE-(1-34) IN MAN [J].
FRAHER, LJ ;
HODSMAN, AB ;
JONAS, K ;
SAUNDERS, D ;
ROSE, CI ;
HENDERSON, JE ;
HENDY, GN ;
GOLTZMAN, D .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (02) :417-423
[5]   COMPARISON OF THE PHARMACOKINETICS OF PARENTERAL PARATHYROID HORMONE-(1-34) [PTH-(1-34)] AND PTH-RELATED PEPTIDE-(1-34) IN HEALTHY-YOUNG HUMANS [J].
FRAHER, LJ ;
KLEIN, K ;
MARIER, R ;
FREEMAN, D ;
HENDY, GN ;
GOLTZMAN, D ;
HODSMAN, AB .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (01) :60-64
[6]  
Henderson JE, 1996, J CELL PHYSIOL, V169, P33, DOI 10.1002/(SICI)1097-4652(199610)169:1<33::AID-JCP4>3.0.CO
[7]  
2-F
[8]   INCREASE OF VERTEBRAL DENSITY BY COMBINATION THERAPY WITH PULSATILE 1-38HPTH AND SEQUENTIAL ADDITION OF CALCITONIN NASAL SPRAY IN OSTEOPOROTIC PATIENTS [J].
HESCH, RD ;
BUSCH, U ;
PROKOP, M ;
DELLING, G ;
RITTINGHAUS, EF .
CALCIFIED TISSUE INTERNATIONAL, 1989, 44 (03) :176-180
[9]   EFFECTS OF CONTINUOUS AND INTERMITTENT ADMINISTRATION AND INHIBITION OF RESORPTION ON THE ANABOLIC RESPONSE OF BONE TO PARATHYROID-HORMONE [J].
HOCK, JM ;
GERA, I .
JOURNAL OF BONE AND MINERAL RESEARCH, 1992, 7 (01) :65-72
[10]   A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis [J].
Hodsman, AB ;
Fraher, LJ ;
Watson, PH ;
Ostbye, T ;
Stitt, LW ;
Adachi, JD ;
Taves, DH ;
Drost, D .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (02) :620-628